Could methylene blue partially bypass an AFG2B/55LCC defect rather than rescue the mutant protein itself?

Hypothesis

Methylene blue could partially compensate for downstream consequences of impaired AFG2B/55LCC function without directly correcting the mutant AFG2B protein.

AFG2B is the ATPase component of the 55LCC complex, which is involved in late 60S ribosomal-subunit maturation. Pathogenic AFG2B dysfunction can therefore plausibly propagate beyond the mutant protein itself into altered ribosome maturation, protein synthesis, proteostasis, and cellular stress.

For the A681P variant specifically, structural and computational analyses place the substitution within a buried helix of the D2 AAA+ ATPase domain. The current model predicts altered conformational dynamics rather than direct disruption of the ATP-binding site or obvious loss of the overall 55LCC architecture.

Methylene blue has a very different mechanism. At low concentrations, it is a reversible redox-active molecule with reported effects on mitochondrial electron transfer, cellular redox state, and bioenergetics.

This suggests a testable possibility:

AFG2B dysfunction > impaired 55LCC activity > abnormal 60S maturation / protein homeostasis > increased cellular functional stress

while, in parallel:

methylene blue > altered redox/electron transfer > improved bioenergetic resilience > partial compensation for downstream functional consequences.

Under this model, methylene blue would function as a bypass rather than a molecular rescue. It would not need to bind AFG2B, restore the A681P structure, or normalize intrinsic 55LCC ATPase activity to produce a measurable downstream benefit.

Predictions

If the bypass hypothesis is correct:

1. AFG2B protein abundance may remain abnormal or unchanged after methylene blue treatment.

2. 55LCC assembly and/or intrinsic ATPase dysfunction may persist.

3. Cellular redox or bioenergetic measures could improve.

4. Protein-synthesis capacity, stress tolerance, or other downstream cellular phenotypes could improve despite persistence of the proximal AFG2B defect.

5. Some downstream ribosome-maturation phenotypes, such as abnormal RSL24D1 handling, could potentially improve without complete normalization of AFG2B itself.

Experimental Tests

A useful experiment would compare A681P/null patient-derived cells or an isogenic A681P model with matched controls, before and after methylene blue exposure.

Measure the proximal disease pathway:

AFG2B abundance > 55LCC assembly > complex-normalized ATPase activity > RSL24D1 / 60S maturation

alongside downstream functional measures:

cellular redox state > mitochondrial respiration / ATP > global protein synthesis > cellular stress and viability.

The most informative result would be improvement in downstream function while the proximal AFG2B defect remains measurable. That pattern would support a compensatory bypass mechanism rather than direct molecular rescue.

What would falsify this?

The hypothesis would be weakened if methylene blue produces no reproducible improvement in relevant downstream phenotypes across a biologically plausible concentration range.

It would also need revision if any observed benefit is better explained by nonspecific stress responses, hormesis, or another mechanism unrelated to the proposed redox/bioenergetic pathway.

I am particularly interested in alternative mechanistic explanations and in assays that could cleanly distinguish:

• direct rescue of AFG2B/55LCC

• downstream metabolic compensation

• nonspecific hormetic effects

What experiment would best separate those three possibilities?